Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
---|
06/16/2004 | EP1428832A2 Peptide and O-glycan inhibitors of selectin mediated inflammation |
06/16/2004 | EP1428820A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications |
06/16/2004 | EP1428524A1 Pulmonary delivery of aerosolized medicaments |
06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
06/16/2004 | EP1427732A1 Spirocyclic-6,7-dihydro-5h-pyrazolo 1,2-a]pyrazol-1-ones which control inflammatory cytokines |
06/16/2004 | EP1427728A1 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES |
06/16/2004 | EP1427727A1 Compounds which inhibit the release of inflammatory cytokines |
06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
06/16/2004 | EP1427696A1 Ccr-3 receptor antagonists v |
06/16/2004 | EP1427438A2 Inflammation modulatory compound comprising an endomorphin |
06/16/2004 | EP1427436A2 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
06/16/2004 | EP1427434A2 Anti-inflammatory agent |
06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
06/16/2004 | EP1427414A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines |
06/16/2004 | EP1427412A1 Methods of treating cytokine mediated diseases |
06/16/2004 | EP1427405A2 Inflammation-inhibiting compounds |
06/16/2004 | EP1427402A1 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |
06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
06/16/2004 | EP1257556B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
06/16/2004 | EP1244643B1 Tryptase inhibitors |
06/16/2004 | EP1200096B1 Tixocortol pivalate suspension, mouth-wash based thereon and packaging containing same |
06/16/2004 | EP1196418B1 METHOD FOR PREPARING SUBSTITUTED 1,4]DIAZEPINO 6,7,1- i hi /i ]INDOL-4-ONES |
06/16/2004 | EP1194411B1 Benzoylpyridazines |
06/16/2004 | EP1173194B1 Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation |
06/16/2004 | EP1144425B1 Derivatives of monosaccharides as cell adhesion inhibitors |
06/16/2004 | EP1109810B1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
06/16/2004 | EP0977725B1 New fatty acid derivatives |
06/16/2004 | EP0977554B1 Confectionery compositions |
06/16/2004 | EP0906102B1 A process for regulating vagal tone |
06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
06/16/2004 | CN1505630A Pyrazolo[1,5-a]pyridines and medicaments containing thereof |
06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
06/16/2004 | CN1505626A Novel benzylpiperidine compound |
06/16/2004 | CN1505624A Piperazino-derivatives and their use as pde4 inhibitor |
06/16/2004 | CN1505513A Aqueous cilostazol preparation for injection |
06/16/2004 | CN1505505A Composition for administration to mucosa and containing coenzyme Q as active ingredient |
06/16/2004 | CN1504752A Vaughan Tristan J. |
06/16/2004 | CN1504198A Compound containing arsenic for prevention and treatment of cough and gasp , and reducing weight and fat |
06/16/2004 | CN1153773C Salts of optically active sulfoxide derivative |
06/16/2004 | CN1153573C Application of bamboo rat's serum and medicine containing said serum |
06/15/2004 | US6750360 Lipoxin compounds and their use in treating cell proliferative disorders |
06/15/2004 | US6750253 Aminobenzophenones as inhibitors of il-1β and tnf-α |
06/15/2004 | US6750232 2-aminopyridine compounds and use thereof as drugs |
06/15/2004 | US6750226 For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease |
06/15/2004 | US6750210 Formulation containing novel anti-inflammatory androstane derivative |
06/15/2004 | US6750202 Inhibitors of procollagen c-proteinase (pcp), for treating fibrosis of the liver |
06/15/2004 | US6749851 Applying radiation |
06/15/2004 | CA2261872C Methods of treating asthma with o-desulfated heparin |
06/15/2004 | CA2159330C Inhibition of leukocyte adhesion |
06/13/2004 | CA2451267A1 Pharmaceutical uses for alpha2delta ligands |
06/10/2004 | WO2004048574A1 Immunoreceptor proteins |
06/10/2004 | WO2004048565A1 Apoptosis-associated protein and use thereof |
06/10/2004 | WO2004048401A1 Peptides and medicinal compositions containing the same |
06/10/2004 | WO2004048391A1 Silicon compounds to be used as ligands for retinoid receptors |
06/10/2004 | WO2004048373A1 Carbamic acid esters with an anticholinergic action |
06/10/2004 | WO2004048326A1 Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient |
06/10/2004 | WO2004048322A1 Cannabinoid receptor ligands |
06/10/2004 | WO2004047925A2 Therapeutic oxidation catalysts |
06/10/2004 | WO2004047829A1 New synergistic combination comprising roflumilast and formoterol |
06/10/2004 | WO2004047828A1 Synergistic combination compresing roflumilas and (r.r) -formoterol |
06/10/2004 | WO2004047824A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
06/10/2004 | WO2004035092A3 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases |
06/10/2004 | WO2004022569A9 Akt inhibitors, pharmaceutical compositions, and uses thereof |
06/10/2004 | WO2004016578A3 Arylethanolamine beta2-adrenoreceptor agonist compounds |
06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
06/10/2004 | WO2004003235A3 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
06/10/2004 | WO2004000225A3 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
06/10/2004 | WO2003102140A3 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis |
06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
06/10/2004 | WO2003080037A3 Use of ltb4 antagonists in veterinary medicine |
06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
06/10/2004 | WO2003066005A3 Ansamycins having improved pharmacological and biological properties |
06/10/2004 | WO2003035049A3 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
06/10/2004 | WO2003024433A3 Compositions for treatment of common cold, comprising ipratropium and xylometazoline |
06/10/2004 | WO2003015711A3 Combination motif immune stimulatory oligonucleotides with improved activity |
06/10/2004 | WO2002090600A3 A method for regulating immune function in primates using the foxp3 protein |
06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
06/10/2004 | US20040110945 Very Late Antigen (Vla-4); such as 4-((4S)-fluoro-1-(2-phenylamino-6-benzoxazolylacetyl)-(2S)-pyrrolidinylmethoxy)benzoic acid; for treatment of inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, and diabetes |
06/10/2004 | US20040110840 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
06/10/2004 | US20040110833 administering a patient an ester of an alpha-ketoalkanoic acid selected from alpha-ketopropionic acid (pyruvate), alpha-keto-butyrate, alpha-ketopentanoate, alpha-keto-3-methyl-pentanoate etc. to treat cytokine mediated inflammatory conditions |
06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
06/10/2004 | US20040110809 di- and tricycle-substituted imidazolidine-, oxazolidine- and thiazolidine diones and thiones, e.g., 5-[p-(quinolin-3-yl)-alpha-hydroxybenzyl]-5-methylimidazolidinedione |
06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
06/10/2004 | US20040110793 Heterocyclo inhibitors of potassium channel function |
06/10/2004 | US20040110768 (S)-3-(1H-indol-3-yl)-N-(1-methoxymethyl-cyclohexylmethyl)-2-methyl-2-[4-(4-nitro-phenyl)-oxazol-2-ylamino]-propionamide for example; cancer, psychological disorders, sexual disorders, eating disorders, inflammatory bowel disease, sleep disorders |
06/10/2004 | US20040110763 Pyrazolopyridine compound and pharmaceutical use thereof |
06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
06/10/2004 | US20040110753 Tyrosine derivatives |
06/10/2004 | US20040110752 2-amino-5-((hetero)aryl)-thiazole derivatives; treatment of disorders such as cancer, immunologic disorders and allergic disorders, optionally in combination with other drugs such as immunosuppressants |
06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
06/10/2004 | US20040110734 Combinations for the treatment of inflammatory disorders |
06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |